ArticleScientific reports2025
Causal role of immunophenotypes in HIV-1 acquisition: insights from Mendelian randomization analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HIV Infection, Neurotoxicity, Inflammation, Premature Aging, and Therapeutic Challenges to PLWH: An Overview.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The acquisition of human immunodeficiency virus (HIV) is influenced by environmental and genetic factors, such as viral inoculum dose, host behavior, and immune responses. Despite advances in understanding HIV pathogenesis, no effective vaccine exists, underscoring the urgent need to deepen our comprehension of host immune mechanisms to enhance preventive strategies. Genetic predisposition and certain immunity characteristics of the host might play essential roles in the risk of HIV-1 acquisition. Mendelian randomization (MR) and colocalization analysis are utilized to investigate the causal relationships between immune responses and HIV-1 risk, aiming to identify targets for potential eradication strategies. We employed a two-sample MR approach to explore the causal links between 731 immunophenotypes and HIV-1 acquisition, using genetic variants from publicly available GWAS summary statistics as instrumental variables. Sources included GWAS data for immune traits and a meta-analysis from European cohorts for HIV-1 acquisition. We validated our findings using Summary-data-based MR analysis, integrating eQTL and mQTL data from the GTEx project. Bayesian colocalization analysis was conducted to identify shared causal variants. Functional and pathway enrichment analysis employing Metascape and Enrichr websets were performed to elucidate potential biological pathways linking immunephenotypes to HIV-1 risk. Our MR analysis identified significant causal associations between 26 specific immunophenotypes and HIV-1 acquisition, indicating a causal association with HIV risk. Colocalization analysis showed that none demonstrated genome-wide evidence of genetic colocalization (regional PP.H4.abf > 0.70). SMR and HEIDI analysis confirmed pleiotropic associations, particularly noting CCR2 on granulocytes as significant. Functional enrichment analysis of 39 SMR-identified genes revealed critical pathways linking immunophenotypes to HIV-1 susceptibility. The "NABA MATRISOME ASSOCIATED" canonical pathway emerged as the most significant pathway using Metascape. Protein-protein interaction networks demonstrated 5 functionally cohesive clusters. Multi-database analyses using Enrichr Analysis revealed functionally similar pathway enrichment: Cell cycle regulation ("G2 Phase", Reactome; "G1/S Control", WikiPathways), shedding light on crucial immune regulation mechanisms potentially instrumental in HIV-1 acquisition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.